Early Clinical Trials Forum of the ECMC network
Agenda
| 10:00 - 10:20 | Registration and refreshments |
| 10:20 - 10:30 | Welcome |
|
Herbie Newell Clinical and Translational Research and Research Strategy Directorate, Cancer Research UK, London |
|
| 10:30 - 11:30 | Introductory Session |
|
Chair: Ruth Plummer Northern Institute for Cancer Research, The Medical School, Newcastle upon Tyne |
|
| 10:30 - 11:00 |
Early phase clinical trials in oncology - an industry perspective Peter Ho Oncology Drug Discovery, GlaxoSmithKline, USA |
| 11:00 - 11:30 |
Academic Phase I trials - to MTD or not to MTD Hilary Calvert Northern Institute for Cancer Research, The Medical School, Newcastle upon Tyne |
| 11:30 - 12:40 | Morning Session |
|
Chair: Christian Ottensmeier Cancer Sciences Division, Southampton General Hospital |
|
| 11:30 - 11:50 |
Phase 1 Targeted Combination Therapies Janet Dancey Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, USA |
| 11:50 - 12:10 |
Novel approaches in antibody therapy Peter Johnson Cancer Research UK Clinical Centre, Southampton General Hospital |
| 12:10 - 12:30 | Integrating Imaging into Early Phase Trial Design John Griffiths Molecular Imaging (MRI and MRS), Cancer Research UK Cambridge Research Institute |
| 12:30 - 12:40 |
General discussion |
| 12:40 - 14:00 | Networking Lunch |
| 14:00 - 16:00 | Afternoon Workshops |
| Workshop 1 |
Immunotherapeutics Session co-ordinator: Christian Ottensmeier Cancer Sciences Division, Southampton General Hospital, Southampton |
| 14:00 - 14:05 | Introduction Christian Ottensmeier Cancer Sciences Division, Southampton General Hospital, Southampton |
| 14:05 - 14:30 |
Preclinical and clinical experience with oncolytic virotherapy and chemo/radiotherapy Kevin Harrington Royal Marsden Hospital, London |
| 14:30 - 14:55 |
Targeting the bone marrow: radiolabelled antibody therapy in haematopoietic stem cell transplantation Kim Orchard Southampton University Hospitals, Southampton |
| 14:55 - 15:20 | Antibody mediated immunologic approach to treating cancer Milayna Subar Global Medical Team - Oncology, Pfizer, New York, USA |
| 15:20 - 15:45 | Electroporation for the delivery of DNA for immunotherapy Iacob Mathiesen Inovio AS, Oslo, Norway |
| 15:45 - 16:00 |
General discussion |
| Workshop 2 |
Translational Radiotherapy and Innovations in Radiotherapy Session co-ordinators: Gillies McKenna Radiation Oncology & Biology, University of Oxford Catharine West Academic Radiation Oncology, University of Manchester |
| 14:00 - 14:10 |
Introduction Gillies McKenna Radiation Oncology & Biology, University of Oxford |
| 14:10 - 14:30 |
Intensity modulated radiotherapy in head and neck cancer Chris Nutting Head and Neck Unit, Royal Marsden Hospital, London |
| 14:30 - 14:50 |
Chemoradiotherapy in rectal cancer Simon Gollins North Wales Cancer Centre, Glan Clwyd Hospital, Rhyl |
| 14:50 - 15:10 |
Radiotherapy in combination with vascular disrupting agents Peter Hoskin Marie Curie Research Wing, Mount Vernon Hospital, Middlesex |
| 15:10 - 15:30 |
Combinations with signal transduction targeting agents Thomas Brunner Radiation Oncology & Biology, University of Oxford |
| 15:30 - 15:40 | Is translational research important in the design of early clinical trials involving radiotherapy? Catharine West Academic Radiation Oncology, University of Manchester |
| 15:40 - 16:00 |
General discussion |
| Workshop 3 |
Cancer Research UK Phase I / II committee workshop Session co-ordinators: Hilary Calvert Northern Institute for Cancer Research, The Medical School, Newcastle upon Tyne Kate Searle Cancer Research UK Drug Development Office (DDO), London |
| 14:00 - 14:05 |
Overview of DDO activities and intitiatives Kate Searle Cancer Research UK Drug Development Office (DDO), London |
| 14:05 - 14:35 |
CR-UK trials of Antibody Directed Enzyme Prodrug Therapy (ADEPT): methods of response assessment, results and proposed Phase II Richard Begent Department of Oncology, Royal Free & University College Medical School, London |
| 14:35 - 14:55 |
The CR-UK Phase I/II trial of I131-CHT25 : CHT25 is effective in relapsed Hodgkin’s and T-cell lymphomas, results and future potential Gairin Dancey Royal Free & University College Medical School, London |
| 14:55 - 15:15 |
Combining antivascular therapy and radioimmunotherapy: results of the CR-UK Phase I trial of I131-A5B7 combined with Combretastatin (CA4P) Tim Meyer Academic Department of Oncology, Royal Free & University College Medical School, London |
| 15:15 - 15:35 |
Pharmacokinetically-directed drug development: the CR-UK Phase I trial of CB1954 combined with EP0152R Mark Middleton Cancer Research UK Medical Oncology Unit, Churchill Hospital, University of Oxford |
| 15:35 - 16:00 |
Pharmacodynamically-directed drug development: the Phase I and II trials of Patrin 2 (Lomeguatrib) Mark Middleton Cancer Research UK Medical Oncology Unit, Churchill Hospital, University of Oxford |
